Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 0.15% & 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia
Phase of Trial: Phase II/III
Latest Information Update: 23 Feb 2019
At a glance
- Drugs SM 04554 (Primary)
- Indications Alopecia
- Focus Registrational; Therapeutic Use
- Sponsors Samumed
- 22 Nov 2018 New trial record
- 19 Nov 2018 According to a Samumed media release, this study is conducted under an IND with the FDA. In addition, the Ministry of Health of Turkey has confirmed that the study, if successful, would support submission of a marketing application for SM04554 in Turkey.
- 19 Nov 2018 According to a Samumed media release, first patient has been dosed in the trial.